OpenNashEarnings

Life Sciences · NYSE: A

Agilent earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends October · next results expected around 23 Nov 2026

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 FY2026

Agilent's new 9500 ICP-MS and flagship GCs launched to orders above plan, while early pharma reshoring orders from five of the top 10 pharma companies back a multi-year instrument cycle.

Demand strengthened across Agilent's largest end markets. Pharma grew 12%, helped by biotech spending, GLP-1 testing and nearly 30% growth in the specialty CDMO business. China returned to growth after a flat expectation, with wins at two leading CXOs and in PFAS testing. Launches from the June ASMS conference are ahead of plan. These include the 9500 ICP-MS, the 8890B and 8860B GCs and the Altura column family. Instrument orders have met or exceeded revenue for ten straight quarters, and the BioCare acquisition added antibody menu to pathology.

Read the Q3 FY2026 summary →Q3 FY2026 slides (PDF) ↗

Quarters

KPI history

Revenue$1.9B+8.1% y/yQ3 FY26
Q4 FY24: $1.7B (worked out from the annual figure)Q4 24$1.7BQ1 FY25: $1.7BQ1 25$1.7BQ2 FY25: $1.7BQ2 25$1.7BQ3 FY25: $1.7BQ3 25$1.7BQ4 FY25: $1.9B (worked out from the annual figure)Q4 25$1.9BQ1 FY26: $1.8BQ1 26$1.8BQ2 FY26: $1.8BQ2 26$1.8BQ3 FY26: $1.9BQ3 26$1.9B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$1.7B *
Q1 FY25$1.7B
Q2 FY25$1.7B
Q3 FY25$1.7B
Q4 FY25$1.9B *
Q1 FY26$1.8B
Q2 FY26$1.8B
Q3 FY26$1.9B
Diluted EPS (GAAP)$1.28+8.5% y/yQ3 FY26
Q1 FY25: $1.11Q1 25$1.11Q2 FY25: $0.75Q2 25$0.75Q3 FY25: $1.18Q3 25$1.18Q1 FY26: $1.07Q1 26$1.07Q2 FY26: $1.20Q2 26$1.20Q3 FY26: $1.28Q3 26$1.28
Data
Q1 FY25$1.11
Q2 FY25$0.75
Q3 FY25$1.18
Q1 FY26$1.07
Q2 FY26$1.20
Q3 FY26$1.28

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin23.6%+2.9 pts y/yQ3 FY26
Q4 FY24: 24.0%Q4 2424.0%Q1 FY25: 22.4%Q1 2522.4%Q2 FY25: 18.0%Q2 2518.0%Q3 FY25: 20.7%Q3 2520.7%Q4 FY25: 23.8%Q4 2523.8%Q1 FY26: 19.6%Q1 2619.6%Q2 FY26: 21.7%Q2 2621.7%Q3 FY26: 23.6%Q3 2623.6%
Data
Q4 FY2424.0%
Q1 FY2522.4%
Q2 FY2518.0%
Q3 FY2520.7%
Q4 FY2523.8%
Q1 FY2619.6%
Q2 FY2621.7%
Q3 FY2623.6%
Free cash flow$439.0M+69.5% y/yQ3 FY26
Q4 FY24: $388.0MQ4 24$388.0MQ1 FY25: $334.0MQ1 25$334.0MQ2 FY25: $107.0MQ2 25$107.0MQ3 FY25: $259.0MQ3 25$259.0MQ4 FY25: $452.0MQ4 25$452.0MQ1 FY26: $175.0MQ1 26$175.0MQ2 FY26: $201.0MQ2 26$201.0MQ3 FY26: $439.0MQ3 26$439.0M
Data
Q4 FY24$388.0M
Q1 FY25$334.0M
Q2 FY25$107.0M
Q3 FY25$259.0M
Q4 FY25$452.0M
Q1 FY26$175.0M
Q2 FY26$201.0M
Q3 FY26$439.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$1.7Bd$1.7B$1.7B$1.7B$1.9Bd$1.8B$1.8B$1.9B
Operating income$408.0Md$376.0M$300.0M$360.0M$443.0Md$353.0M$399.0M$444.0M
Operating margin24.0%22.4%18.0%20.7%23.8%19.6%21.7%23.6%
Net income$351.0Md$318.0M$215.0M$336.0M$434.0Md$305.0M$339.0M$362.0M
Diluted EPS—$1.11$0.75$1.18—$1.07$1.20$1.28
Operating cash flow$481.0Md$431.0M$221.0Md$362.0Md$545.0Md$268.0M$277.0Md$519.0Md
Capital expenditure$93.0Md$97.0M$114.0Md$103.0Md$93.0Md$93.0M$76.0Md$80.0Md
Free cash flow$388.0M$334.0M$107.0M$259.0M$452.0M$175.0M$201.0M$439.0M
R&D expense$111.0Md$113.0M$112.0M$111.0M$119.0Md$117.0M$126.0M$123.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings